When GLP-1 receptor agonists like semaglutide or tirzepatide bind to these receptors, one of their effects is slowing the rate at which food moves from the stomach to the small intestine
Here is the science to help you make an informed decision
To date, these GLP-1 drugs have been approved to treat three adult populations: individuals with type 2 diabetes, individuals with a body mass index (BMI) of 30 or greater (obesity), and individuals with a BMI between 27 and 30 (overweight) with at least one weight-related health condition, such as cardiovascular disease, high blood pressure, high cholesterol, prior stroke, prior heart attack, and chest pain (angina)
If youre dealing with obesity or type 2 diabetes today, dont wait
It may take time and a little trial and error
The only thing that changes is how it is distributed across the week